BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 2009;61:674-9. [DOI: 10.1002/art.24461] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Kharagjitsing HHS, Hendriksz TR, Fouraux MA, van Gelder T, van Bommel EFH. Clinical significance of soluble interleukin-2 receptor measurement in patients with idiopathic retroperitoneal fibrosis. Int Urol Nephrol 2022. [PMID: 35359217 DOI: 10.1007/s11255-022-03196-3] [Reference Citation Analysis]
2 Kwok S. The Baseline Serum IgG4/IgG3 Ratio Might be a Suitable Marker for Predicting Favorable Treatment Response in Patients With Idiopathic Retroperitoneal Fibrosis-associated Hydronephrosis. J Rheum Dis 2021;28:53-4. [DOI: 10.4078/jrd.2021.28.2.53] [Reference Citation Analysis]
3 Choi SJ, Oh JS, Hong S, Lee C, Yoo B, Hong B, Kim Y. Treatment Response to Idiopathic Retroperitoneal Fibrosis-associated Hydronephrosis With a Focus on IgG4/IgG3 Serum Concentration Ratio. J Rheum Dis 2021;28:38-44. [DOI: 10.4078/jrd.2021.28.1.38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sheth R, Malik D. Bilateral Hydronephrosis From Retroperitoneal Fibrosis. Cureus 2020;12:e12147. [PMID: 33489559 DOI: 10.7759/cureus.12147] [Reference Citation Analysis]
5 Le Joncour A, Saadoun D, Cacoub P. La fibrose rétropéritonéale idiopathique. Rev Med Interne 2020;41:822-8. [PMID: 32727694 DOI: 10.1016/j.revmed.2020.06.013] [Reference Citation Analysis]
6 Zhao J, Li J, Zhang Z. Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study. Scand J Rheumatol 2019;48:239-45. [PMID: 30270709 DOI: 10.1080/03009742.2018.1497700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kamper L, Dreger NM, Brandt AS, Pöppel T, Abanador-kamper N, Roth S, Haage P. Diffusion-weighted MRI and PET–CT in the follow up of chronic periaortitis. Int J Cardiovasc Imaging 2018;34:1779-85. [DOI: 10.1007/s10554-018-1395-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Terzic B, Spasic M, Djuric P, Vasiljevic V, Radjen S, Mijuskovic M. Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report. Exp Ther Med 2017;13:3603-6. [PMID: 28588687 DOI: 10.3892/etm.2017.4425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med 2017;12:287-99. [DOI: 10.1007/s11739-016-1599-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
10 Laroche AS, Bell RZ, Bezzaoucha S, Földes E, Lamarche C, Vallée M. Retroperitoneal fibrosis: retrospective descriptive study on clinical features and management. Res Rep Urol 2016;8:175-9. [PMID: 27822461 DOI: 10.2147/RRU.S115448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Brandt AS, Kukuk S, Dreger NM, Müller E, Roth S. Diagnostik und Therapie der retroperitonealen Fibrose. Urologe 2016;55:732-40. [DOI: 10.1007/s00120-016-0081-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L. (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging 2016;43:1646-52. [PMID: 26969347 DOI: 10.1007/s00259-016-3351-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
13 Vaglio A, Maritati F. Idiopathic Retroperitoneal Fibrosis. J Am Soc Nephrol 2016;27:1880-9. [PMID: 26860343 DOI: 10.1681/ASN.2015101110] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
14 van der Bilt FE, Hendriksz TR, van der Meijden WA, Brilman LG, van Bommel EF. Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J 2016;9:184-91. [PMID: 26985367 DOI: 10.1093/ckj/sfv148] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
15 Kamper L, Brandt AS, Ekamp H, Abanador-Kamper N, Piroth W, Roth S, Haage P. Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis. Diagn Interv Radiol 2014;20:459-63. [PMID: 25297391 DOI: 10.5152/dir.2014.14027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
16 Kamper L, Haage P, Brandt AS, Piroth W, Abanador-Kamper N, Roth S, Ekamp H. Diffusion-weighted MRI in the follow-up of chronic periaortitis. Br J Radiol 2015;88:20150145. [PMID: 26110205 DOI: 10.1259/bjr.20150145] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
17 Kamper L, Brandt AS, Ekamp H, Hofer M, Roth S, Haage P, Piroth W. The potential role of modern US in the follow-up of patients with retroperitoneal fibrosis. Diagn Interv Radiol 2014;20:3-8. [PMID: 24004976 DOI: 10.5152/dir.2013.13132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Kukuk S, Kretschmer A, Bruck H, Roth S, Brandt A. Retroperitoneale Fibrose: Entwicklung eines Biomarkerprofils zur Diagnostik und Verlaufskontrolle. Urologe 2015;54:52-61. [DOI: 10.1007/s00120-014-3713-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Liu H, Zhang G, Niu Y, Jiang N, Xiao W. Retroperitoneal fibrosis: a clinical and outcome analysis of 58 cases and review of literature. Rheumatol Int 2014;34:1665-70. [DOI: 10.1007/s00296-014-3002-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
20 van Bommel E, Pelkmans L, van Damme H, Hendriksz T. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. European Journal of Internal Medicine 2013;24:444-50. [DOI: 10.1016/j.ejim.2012.11.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
21 Caiafa RO, Vinuesa AS, Izquierdo RS, Brufau BP, Ayuso Colella JR, Molina CN. Retroperitoneal Fibrosis: Role of Imaging in Diagnosis and Follow-up. RadioGraphics 2013;33:535-52. [DOI: 10.1148/rg.332125085] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
22 Brandt AS, Kamper L, Kukuk S, Piroth W, Haage P, Roth S. An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res 2013;5:49-56. [PMID: 23390476 DOI: 10.4021/jocmr1254e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
23 Moroni G, Castellani M, Balzani A, Dore R, Bonelli N, Longhi S, Martinelli I, Messa P, Gerundini P. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 2012;39:1635-42. [PMID: 22801728 DOI: 10.1007/s00259-012-2144-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
24 Pelkmans LG, Aarnoudse AJ, Hendriksz TR, van Bommel EF. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant 2012;27:2819-25. [PMID: 22273666 DOI: 10.1093/ndt/gfr779] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
25 Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozzi F, Corradi D, Salvarani C, Buzio C. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. 2011;378:338-346. [PMID: 21733570 DOI: 10.1016/s0140-6736(11)60934-3] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
26 Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011;86:297-303. [PMID: 21454732 DOI: 10.4065/mcp.2010.0663] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
27 Vaglio A, Pipitone N, Salvarani C. Chronic periaortitis: a large-vessel vasculitis? Current Opinion in Rheumatology 2011;23:1-6. [DOI: 10.1097/bor.0b013e328341137d] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
28 Jansen I, Hendriksz TR, Han SH, Huiskes AW, van Bommel EF. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med. 2010;21:216-221. [PMID: 20493425 DOI: 10.1016/j.ejim.2010.02.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]